Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017


Here are the related meetings in 2018:
Emerging Cellular Therapies: T Cells and Beyond (B6)
Cancer Immunotherapy: Combinations (C5)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)


Organizer(s) Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff
March 19—23, 2017
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 16, 2016
Abstract Deadline: Dec 19, 2016
Scholarship Deadline: Nov 16, 2016
Discounted Registration Deadline: Jan 18, 2017

Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. ,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:
The fields of cancer immunology and immunotherapy continue to make great strides in providing both a comprehensive understanding of the basic mechanisms underlying tumor-immune system interactions and applying this knowledge to the development of effective immune-based cancer therapies. This Keystone Symposia meeting is organized to highlight recent insights into the complex roles of immune components and pathways in controlling or alternatively promoting cancer and to showcase recent uses of cancer vaccines, checkpoint blocking strategies, adoptive cell therapies and cellular engineering approaches, either as mono- or combinatorial therapies, that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients. Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible in the past.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, March 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 23 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 24 in order to fully experience the meeting.

SUNDAY, MARCH 19

4:00—8:00 PM
Arrival and Registration

Macdonald Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, MARCH 20

7:00—8:00 AM
Breakfast

Frontenac/Empress Ballrooms
8:00—9:30 AM
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Robert D. Schreiber, Washington University School of Medicine, USA

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Mechanisms of Protective Tumor Immunity

Andreas G. Plückthun, University of Zürich, Switzerland
Future Biologics: Exploiting the Opportunities for Protein Engineering

Coffee Break

9:50—11:45 AM
Multimodal Approaches to Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Blockade in Cancer Therapy: New Insights and Opportunities

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Genome-Scale CRISPR-Cas9 Screen Identifies Genes Essential for T Cell-Based Cancer Therapies

11:45 AM—5:00 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

Frontenac/Empress Ballrooms
1:00—10:00 PM
Poster Viewing

Frontenac/Empress Ballrooms
2:30—4:30 PM
Workshop 1: Neoantigens, Vaccines and Responses

Macdonald Ballroom
Nicholas K. Akers, Icahn School of Medicine at Mount Sinai, USA
Modeling Tumor Immuno-Dynamics to Predict Patient Survival & Immunotherapy Efficacy

Govinda Sharma, BC Cancer Agency, Canada
A Novel High-Throughput Screening Approach for the Detection of Cytotoxic T-Cell Receptor Epitopes

Sanja Stevanovic, NCI, National Institutes of Health, USA
Landscape of Immunogenic Tumor Antigens in Successful Immunotherapy of Virally-Induced Epithelial Cancer

Alice Tzeng, Cleveland Clinic Lerner College of Medicine, USA
Temporally Programmed CD8alpha+ DC Activation Enhances Combination Cancer Immunotherapy

Aileen Li, Harvard University, USA
Mesoporous Silica (MPS) Vaccine to Enhance Anti-Tumor Immunity

* Jay A. Berzofsky, NCI, National Institutes of Health, USA
Translation of Cancer Vaccines from Mice to Human Clinical Trials

4:30—5:00 PM
Coffee Available

Macdonald Foyer
5:00—7:15 PM
Immunosuppressive Cells in the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Tregs in Cancer Immunity

Vincenzo Bronte, University of Verona, Italy
Role of Myeloid-Derived Suppressor Cells in Tumor Immunity

Alberto Mantovani, Humanitas University, Italy
Role of Macrophages in Tumor Immunity

Garry P. Nolan, Stanford University, USA
System-Wide Order, from Disorder, at the Cancer-Immune Interface

7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
7:30—10:00 PM
Poster Session 1

Frontenac/Empress Ballrooms

TUESDAY, MARCH 21

7:00—8:00 AM
Breakfast

Frontenac/Empress Ballrooms
8:00—11:15 AM
Cancer Immunotherapy: Targeting Immune Checkpoints
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Ira Mellman, Genentech, Inc., USA
PD-1/PD-L1

Riccardo Mezzadra, NKI-AvL, Netherlands
Short Talk: Identification of CMTM6 and CMTM4 as PD-L1 Protein Regulators

Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA
OX40 Agonists: Past, Present and Future

Coffee Break

Ana Carrizosa Anderson, Harvard Medical School, USA
Targeting Tim-3 in Cancer

Randolph J. Noelle, Dartmouth College, USA
Targeting the VISTA Pathway in Oncology

Vinidhra Mani, Harvard Medical School, USA
Short Talk: Visualizing the Mechanistic Basis of Checkpoint Blockade Therapy in Cancer

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Frontenac/Empress Ballrooms
1:00—10:00 PM
Poster Viewing

Frontenac/Empress Ballrooms
2:30—4:30 PM
Workshop 2: Cellular Engineering and Therapy

Macdonald Ballroom
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA

Mauro Castellarin, University of Pennsylvania, USA
A Comparison of Affinity-Tuned Her2 CARs Using a New Mouse Model for On-Target Off-Tumor CAR T Cell Cytotoxicity

Ashwini Balakrishnan, Fred Hutchinson Cancer Research Institute, USA
Designed Ankyrin Repeat Proteins (DARPins) as Recognition Motifs in Chimeric Antigen Receptors

Kristin Anderson, University of Washington, USA
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

Stefanie Bailey, Medical University of South Carolina, USA
CD26high T Cells have a Natural Capacity to Migrate and Persist in Multiple Tumor Models

Natalie Ann Vandeven, University of Washington, USA
Novel Platform for Identifying Rare Antigen-Specific CD4 T Cells in Merkel Cell Carcinoma patients

Debattama Sen, Harvard Medical School, USA
The Epigenetic Landscape of T Cell Exhaustion

4:30—5:00 PM
Coffee Available

Macdonald Foyer
5:00—7:00 PM
Cancer Immunotherapy: Combinatorial Approaches
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Robert D. Schreiber, Washington University School of Medicine, USA
Personalized Cancer Vaccines

Sandra Demaria, Weill Cornell Medical College, USA
Radiotherapy Needs to Go Viral to Increase Responses to Checkpoint Inhibitors

Antoni Ribas, University of California, Los Angeles, USA
Overcoming Resistance to PD-1 Blockade Therapy

Alyssa K. Kosmides, Johns Hopkins University, USA
Short Talk: Immunoswitch Particles: A New Approach to Cancer Immunotherapy

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
7:30—10:00 PM
Poster Session 2

Frontenac/Empress Ballrooms

WEDNESDAY, MARCH 22

7:00—8:00 AM
Breakfast

Frontenac/Empress Ballrooms
8:00—11:15 AM
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Elizabeth M. Jaffee, Johns Hopkins University, USA
Vaccine-Based Combinatorial Immunotherapy Can Convert Pancreatic Cancers into Immunologic Diseases

Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
High-Dimensional Analyses of the Mucosal Microenvironment in Precancerous, Intraepithelial Cervical HPV Disease

Coffee Break

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Developing and Improving Personalized Neoantigen-Targeting Cancer Vaccines

Ugur Sahin, TRON – Translationale Oncology, Germany
Individualizing Cancer Treatment by mRNA Therapies

Danielle M. Lussier, Washington University in St. Louis, USA
Short Talk: Subclinical Irradiation-Induced Neoantigens Enhance Immunotherapy of Cancers with Low Mutational Loads

Amanda Lulu, University of Virginia, USA
Short Talk: Pre-Existing Immune Memory in Healthy Donors to Cancer-Associated Phosphopeptides

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Frontenac/Empress Ballrooms
1:00—10:00 PM
Poster Viewing

Frontenac/Empress Ballrooms
4:30—5:00 PM
Coffee Available

Macdonald Foyer
5:00—7:00 PM
Inflammation and the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Michael Karin, University of California, San Diego, USA
Immune Regulation of Liver Cancer: Chronic Hepatitis Promotes HCC Development by Dismantling Cancer Immunosurveillance

Shannon J. Turley, Genentech, Inc., USA
Leukocyte Function and Positioning in Diverse Stromal Niches

Thomas Gajewski, University of Chicago, USA
Tumor-Intrinsic Mediators of T Cell-Inflamed Versus Non-Inflamed Tumor Microenvironment

Evan W. Newell, Singapore Immunology Network, SigN, Singapore
Short Talk: Deep Profiling of Human Hepatocellular Carcinoma Immune Infiltrates: Involvement of CD103+ Resident Memory-Like T and NK Cells

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
7:30—10:00 PM
Poster Session 3

Frontenac/Empress Ballrooms

THURSDAY, MARCH 23

7:00—8:00 AM
Breakfast

Frontenac/Empress Ballrooms
7:30—8:00 AM
Poster Setup

Frontenac/Empress Ballrooms
8:00 AM—5:00 PM
Poster Viewing

Frontenac/Empress Ballrooms
8:00—11:15 AM
Cancer Immunotherapy: Cellular Engineering
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
* Philip D. Greenberg, University of Washington, USA
Adoptive T Cell Therapy with TCR-Engineered T Cells

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Targeting CARs to the TRAC Locus Enhances T Cell Potency

Coffee Break

Carl H. June, University of Pennsylvania, USA
CAR-T Therapy of ALL

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
CAR-T Cells for Hematopoietic and Solid Tumors

Agne Taraseviciute, Seattle Children's Research Institute, USA
Short Talk: A Non-Human Primate Model That Recapitulates B Cell-directed Chimeric Antigen Receptor (CAR) T cell-mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity

Daniel T. Harris, University of Illinois, USA
Short Talk: A Comparison of T Cell Sensitivity using TCR and CAR Constructs with the Same pepMHC Binding Domain

11:15 AM—12:15 PM
Lunch

Frontenac/Empress Ballrooms
12:00—2:30 PM
Poster Session 4

Frontenac/Empress Ballrooms
2:30—4:30 PM
Workshop 3: A Deeper Dive into Cancer Immunotherapy

Macdonald Ballroom
* Evan W. Newell, Singapore Immunology Network, SigN, Singapore

Brian Christopher Miller, Dana-Farber Cancer Institute, USA
Dissecting Mechanisms of anti-PD-1 Therapy with Massively Parallel Single-Cell RNA-Sequencing

Wouter Scheper, Netherlands Cancer Institute, Netherlands
Unbiased Single-Cell TCR Analysis Reveals Infrequent Tumor-Reactivity Among T Cells Infiltrating Human Cancers

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Distinct Cellular Mechanisms Mediate Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Yonit Lavin, Mount Sinai School of Medicine, USA
High Dimensional Analysis of Untreated Early Lung Cancer Lesions Reveals Novel Myeloid Immune Responses to Tumor

Ken-Edwin Aryee, University of Massachusetts Medical School, USA
Humanized Mouse; A Model for Understanding Tumor-Immune System Interactions

Aya Ludin Tal, Harvard University, USA
The Zebrafish as a Model for T Cell Recruitment to Melanoma

4:30—5:00 PM
Coffee Available

Macdonald Foyer
5:00—6:45 PM
Nex-Gen Technologies
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combining Lymph Node Targeting Cancer Vaccines with Systemic Immunotherapy to Recruit an Innate and Adaptive Attack Against Established Tumors

* Lisa M. Coussens, Oregon Health & Science University, USA
Monitoring Inflammation in Cancer by Multi-Plex in situ Imaging

Jim R. Heath, California Institute of Technology, USA
Micro- and Nanotechnologies for Personalizing Cancer Immunotherapy

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Macdonald Ballroom
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac

FRIDAY, MARCH 24

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Astellas Pharma Inc. AstraZeneca
Bill & Melinda Gates Foundation BioLegend, Inc.
Bristol-Myers Squibb Company Cell Research
Cell Signaling Technology, Inc. Genentech, Inc.
Genmab A/S ImmunoGen, Inc.
Incyte Corporation Juno Therapeutics
Merck & Co., Inc. Mersana Therapeutics
MorphoSys AG OncoMed Pharmaceuticals, Inc.
Pfizer Inc. Regeneron Pharmaceuticals, Inc.
Roche Sangamo Therapeutics, Inc.
Takeda Pharmaceutical Company Limited TESARO, Inc.

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Adipogen International American Association for Cancer Research (AACR)
Cellcion, LLC InSphero Inc.
Opsona Therapeutics Ltd Personalis Inc.
ProSci Inc.
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA216951-01

Funding for this conference was made possible (in part) by CA216951-01 from the National Institutes of Heath. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Journal for the Immunotherapy of Cancer (BioMed Central Ltd)

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676